Form 4: LEMAITRE VASCULAR Director Sells Shares

A director at LEMAITRE VASCULAR INC exercised stock options and subsequently sold a significant number of shares in early August 2025.

Summary

• John A. Roush, a Director of LEMAITRE VASCULAR INC, engaged in significant stock transactions in August 2025.
• On August 8, 2025, 939 shares of common stock were acquired through option exercise at $37.29 per share and subsequently sold at a weighted average price of $93.4872 per share.
• On August 11, 2025, 6,561 shares of common stock were acquired through option exercise at $37.29 per share.
• Also on August 11, 2025, 4,987 shares were sold at a weighted average price of $92.783 per share, and an additional 1,574 shares were sold at a weighted average price of $91.8181 per share.
• Following these transactions, beneficial ownership of common stock stands at 2,916 shares.
• The exercised stock options were fully vested and exercisable as of December 2, 2020, and are set to expire on December 2, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, these transactions are often pre-planned for diversification or liquidity purposes and do not necessarily reflect a change in the company's fundamental outlook. The director realized significant gains from option exercises.

Positives

• The director realized substantial gains by exercising stock options at a strike price of $37.29 and selling shares at prices ranging from $91.8181 to $93.4872.
• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned sales rather than a reaction to immediate company news.

Negatives

• The director's direct beneficial ownership of common stock decreased from an initial 3,855 shares (before the first transaction on 08/08/2025) to 2,916 shares after all reported transactions.
• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces insider alignment with shareholder interests.

Future Outlook

This filing is a report of insider transactions and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing details specific insider trading activity for LEMAITRE VASCULAR INC, a company operating in the medical devices sector, specifically vascular products. Such transactions are common for executives and directors for personal financial planning and do not inherently reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders may interpret the director's sale of shares differently; some may view it as a normal part of personal financial planning, especially given the pre-planned nature (10b5-1), while others might perceive it as a reduction in insider alignment.

Key Dates

Recommendation

The filing details a director's exercise of stock options and subsequent sale of shares. While insider selling can sometimes be viewed negatively, these transactions are often pre-planned for diversification or liquidity purposes and do not necessarily reflect a change in the company's fundamental outlook. Without additional financial or strategic information, a 'hold' recommendation is appropriate as this filing alone does not provide sufficient grounds for a strong directional call.

Keywords

LEMAITRE VASCULAR, LMAT, Insider Trading, Form 4, Stock Options, Director Stock Sale, Medical Devices, Vascular